

September 8, 2016



CymaBay Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

NEWARK, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies to treat diseases with high unmet medical need, today announced that management will present a corporate overview at the Rodman & Renshaw 18th Annual Global Investment Conference.

Rodman & Renshaw 18th Annual Global Investment Conference

Date: Monday, September 12
Time: 3:25pm – 3:50pm Eastern Time
Place: The Lotte New York Palace Hotel, Adams Room
Webcast: <http://ir.cymabay.com/events>

About CymaBay

CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat diseases with high unmet medical need, including serious rare and orphan disorders. MBX-8025 is a potent, selective, orally active PPAR δ agonist. CymaBay has recently completed a Phase 2 study of MBX-8025 in patients with primary biliary cholangitis as well as a pilot Phase 2 study in patients with homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Previously, a Phase 2 study of MBX-8025 in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. Arhalofenate, CymaBay's other product candidate, is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in gout patients. Arhalofenate has been found to reduce painful flares in joints while at the same time promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia.

For additional information about CymaBay visit www.cymabay.com.

Contact:
Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800
Investors@CymaBay.com

Hans Vitzthum
LifeSci Advisors, LLC
212-915-2568
Hans@LifeSciAdvisors.com



Source: CymaBay Therapeutics, Inc.